Abstract-In isolated rat hepatocytes, mepacrine stimulated the conversion of [1 -14C] oleate into 14C02 and depressed the formation of acid-soluble products from [1 -14C] oleate.
The action of mepacrine on [1-14C]oleate oxidation was not affected by exogenously applied phospholipase A2 (from Crota/us adamanteus venom) or arachidonic acid.
It is suggested that mepacrine may exert its metabolic effects in isolated rat hepatocytes by a mechanism independent of phospholipase A2 inhibition.
Mepacrine exerts biological activities in platelets and isolated pancreatic islets, i.e., inhibition of platelet aggregation induced by thrombin (1) and suppression of glucose induced insulin secretion (2) . These me pacrine actions have been explained on the basis of the inhibition of cellular phos pholipase A2 (3). Therefore, mepacrine ap pears to be a good probe for investigating the possible role of phospholipase A2 acti vation in hormone action. The action of vaso pressin on isolated rat hepatocytes has been found to be associated with the release of arachidonic acid or its metabolites (4) . We initially attempted to test whether mepacrine antagonizes vasopressin's action on [1-14C] oleate oxidation in isolated rat hepatocytes, i.e., the stimulation of 14C02 production from [1-14C] Mepacrine markedly stimulated [1-14C] oleate oxidation to 14C02 and markedly de pressed the formation of acid-soluble pro ducts (mainly ketone bodies) from [1-14C] oleate. The dose-response curve indicates that 0.5 mM mepacrine increased 14C02 production to about 184% of the control (Fig.  1A) and depressed the formation of acid soluble products to about 21% of the control (Fig. 1B) BPB (0.25 mM), phenidone (0.25 mM), indomethacin (0.5 mM), NDGA (0.5 mM), BHT (0.5 mM) and mepacrine (0.25 mM) did not affect hepatocyte ATP content (con trol, 2.02±0.08 umol/g wet wt.; BPB, 1.96± 0.10; phenidone, 1.96±0.08; indomethacin, 1.97±0.07; NDGA, 1.95±0.10; BHT, 2.00± 0.06; mepacrine, 2.12±0.13, N=4), sug gesting that these agents exerted no toxic injury to hepatocytes.
To find out whether the actions of me pacrine and phenidone in isolated rat hepa tocytes are associated with the inhibition of phospholipase A2 activity or that of arachido nic acid metabolism, the effects of exoge nously applied phospholipase A2 and arachidonic acid were examined. Neither phospholipase A2 (1 U/ml) nor arachidonic acid (100 ,aM) antagonized mepacrine's (0.25 mM) action on 14C02 production (control, 1.16±0.03 itmol oleate utilized/30 min/g wet wt.; phospholipase A2, 1.05±0.02; arachido nic acid, 1.16±0.04; mepacrine, 1.87±0.13; mepacrine plus phospholipase A2, 1.82± 0.08; mepacrine plus arachidonic acid, 1.88± 0.07, N=4) and the formation of acid-soluble products (control, 3.62±0.45 amol oleate utilized/30 min/g wet wt.; phospholipase A2, 3.79±0.34; arachidonic acid, 3.44±0.53; mepacrine, 1.45±0.13; mepacrine plus phos pholipase A2, 1.51±0.11, mepacrine plus arachidonic acid, 1.46±0.31, N=4). The effect of phenidone on 14C02 production was also not affected by these exogenously ap plied substances (results not shown). Our data suggest that mepacrine as well as phenidone may affect [1-14C] oleate me tabolism in the liver by mechanisms in dependent of their well-known effects on phospholipase A2 activity or arachidonic acid metabolism. Barritt et al. (9) documented that mepacrine stimulates inositol utilization in isolated rat hepatocytes. Furthermore, mepacrine has been shown to be a potent inhibitor of phosphatidic acid phosphatase (15) and acyl coenzyme A: lysolecithin acyl transferase (16) . Whether these actions of mepacrine are associated with the regulation of [1-14C] oleate metabolism needs to be further investigated. Uncoupling of oxidative phosphorylation in the liver increases citric acid cycle activity (17) , which prevents acetyl units generated by 8-oxidation of oleate from entering the ketogenic pathway and increases C02 production.
Mepacrine, however, is unlikely to act as an uncoupler in isolated rat hepatocytes since the agent did not affect whole-cell ATP content (described above).
